CytoDyn (CYDY) Net Income towards Common Stockholders (2010 - 2026)
CytoDyn (CYDY) reported Net Income towards Common Stockholders of -$19.94 million for fiscal Q1 2027 (quarter ended Aug 31, 2026), compared with -$5.54 million a year earlier.
Powered by 
Analysis
CytoDyn (CYDY) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Over the twelve months ended Aug 31, 2026, CytoDyn's Net Income towards Common Stockholders came in at -$57.83 million; for FY2026 (ended May 31, 2026), it came in at -$44.18 million.
- By fiscal year, Net Income towards Common Stockholders came in at $2.26 million in FY2025, -$49.84 million in FY2024, -$79.82 million in FY2023 and -$210.82 million in FY2022.
- Five-year quarterly Net Income towards Common Stockholders spans a low of -$84.12 million in fiscal Q4 2022 and a high of $19.23 million in fiscal Q1 2025.
- Per Business Quant data, the three fiscal quarters before Q1 2027 came in at -$10.24 million (Q4 2026), -$5.05 million (Q3 2026) and -$22.61 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | -248.00 Mn |
| 10 | CytoDyn | 367.38 Mn | 318.53 Mn | - | -19.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Aug 31, 2026 | -19.94 Mn |
| May 31, 2026 | -10.24 Mn |
| Feb 28, 2026 | -5.05 Mn |
| Nov 30, 2025 | -22.61 Mn |
| Aug 31, 2025 | -5.54 Mn |
| May 31, 2025 | -6.33 Mn |
| Feb 28, 2025 | -5.12 Mn |
| Nov 30, 2024 | -4.77 Mn |
| Aug 31, 2024 | 19.23 Mn |
| May 31, 2024 | -16.79 Mn |
| Feb 29, 2024 | -11.92 Mn |
| Nov 30, 2023 | -9.56 Mn |
| Aug 31, 2023 | -11.57 Mn |
| May 31, 2023 | -18.64 Mn |
| Feb 28, 2023 | -13.70 Mn |
| Nov 30, 2022 | -26.50 Mn |
| Aug 31, 2022 | -20.99 Mn |
| May 31, 2022 | -84.12 Mn |
| Feb 28, 2022 | -41.29 Mn |
| Nov 30, 2021 | -40.08 Mn |
API Access
CytoDyn Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CYDY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "CYDY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CYDY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();